{"entity":{"id":"fs-x2","kind":"drug","name":"FS-X2","aka":[],"tldr":"FS-X2 is an experimental small molecule from Fushi Biotechnology, in preclinical development for CCNE1-positive solid tumours.","summary":"FS-X2 is a small molecule (company platform is fragment-based small-molecule discovery) from Fushi Biotechnology. Targets PKMYT1; the company lists it for CCNE1-positive solid tumours (written 'CCEN1+' on the site). Its furthest stage is preclinical development, for CCNE1-positive solid tumours. No clinical trial naming it is registered on ClinicalTrials.gov. Pipeline milestone: IND 2027 Q2. It has not been shown to work in people.","status":"preclinical","asOf":"2026-11-03","links":[{"label":"Fushi Biotechnology: foresightbiopharm.com","url":"https://www.foresightbiopharm.com/en/pipeline.html"}],"tags":["pipeline"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["fushi-biotechnology"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"FS-X2","modality":"Small molecule (company platform is fragment-based small-molecule discovery)","mechanism":"Targets PKMYT1; the company lists it for CCNE1-positive solid tumours (written 'CCEN1+' on the site).","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/fs-x2/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"fushi-biotechnology","kind":"company","name":"Fushi Biotechnology","route":"/companies/fushi-biotechnology/"}]}}